Potential side effects of microdosing GLP-1 RAs include gastrointestinal issues, unintended weight loss, muscle mass concerns, and a small risk of medullary thyroid carcinoma. — Whalespan
Potential side effects of microdosing GLP-1 RAs include gastrointestinal issues, unintended weight loss, muscle mass concerns, and a small risk of medullary thyroid carcinoma.
⚠ High risk
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
◐PARTIALLYSUPPORTED
⚠
High-risk intervention — consult a physician before acting.Drug-drug interactions, dose-dependence, and screening contraindications apply.
“Even with microdosing, it’s essential to monitor for: Gastrointestinal Issues: Nausea and vomiting are common but less likely at low doses. Unintended Weight Loss: Increased satiety could lead to unintentional caloric restriction, I intend to stick to my 10% caloric restriction regimen. I will be watching out diligently for subcutaneous fat loss, especially in the face. Muscle Mass Concerns: There’s potential for muscle wasting, possibly higher than expected from caloric restriction alone, typically people on GLP-1-RA tend to consume less protein due to appetite loss. Thyroid Health: A small risk of medullary thyroid carcinoma has been noted in animal studies, though not definitively in humans”